3-sulphamoyl-4-chloro-5-aminobenzoic acid | 25317-76-4

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-sulphamoyl-4-chloro-5-aminobenzoic acid
• 英文别名: 3-amino-4-chloro-5-sulfamoylbenzoic acid；3-amino-4-chloro-5-sulfamylbenzoic acid；4-Chlor-5-sulfamyl-metanilsaeure
• CAS: 25317-76-4
• 化学式: C₇H₇ClN₂O₄S
• 分子量: 250.663
• InChiKey: XPWNKJUPBKTKSI-UHFFFAOYSA-N

物化性质

• 熔点：
  261-261.5 °C(Solv: water (7732-18-5))
• 沸点：
  576.7±60.0 °C(Predicted)
• 密度：
  1.726±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  132
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-sulphamoyl-4-chloro-5-aminobenzoic acid 在 硫酸 、 碳酸氢钠 作用下， 以 乙醇 、 乙腈 为溶剂， 生成 ethyl 3-[N-benzyloxycarbonyl-N-(carboxymethyl)-glycinamido]-4-chloro-5-sulfamoylbenzoate
  参考文献：
  名称：

  Compounds for treating hypertension

  摘要：

  式##STR1##及其药用可接受的盐的化合物，其中取代基如本文所定义，具有降压活性。

  公开号：

  US04596791A1
• 作为产物：
  描述：

  4-氯-3-硝基-5-氨磺酰基苯甲酸 在 sodium hydrogensulfite 作用下， 以 水 为溶剂， 以23.9 g (68%)的产率得到3-sulphamoyl-4-chloro-5-aminobenzoic acid
  参考文献：
  名称：

  Compounds for treating hypertension

  摘要：

  式##STR1##及其药用可接受的盐的化合物，其中取代基如本文所定义，具有降压活性。

  公开号：

  US04596791A1

文献信息

• Sulfamylbenzoic acid derivatives
  申请人：Leo Pharmaceutical Products Ltd. A/S

  公开号：US03950376A1

  公开（公告）日：1976-04-13

  Compounds of the general formula ##SPC1## In which R.sub.1 represents a straight or branched C.sub.1 -C.sub.6 alkyl, alkenyl or alkynyl radical, or a C.sub.1 -C.sub.3 alkyl radical substituted with phenyl, halophenyl, trifluoromethylphenyl, (lower alkoxy)phenyl, or with a 5-membered or 6-membered heterocyclic ring containing not more than two heteroatoms selected from the group consisting of oxygen, sulphur and nitrogen; R.sub.2 stands for a phenyl radical, optionally being substituted with halogen, lower alkyl, hydroxy, or lower alkoxy; X and Y stand for oxygen or sulphur; their salts and esters and methods for their preparation. The compounds of the invention possess an outstanding diuretic and saluretic activity with a very low excretion of potassium ions and a low toxicity.

  通式为##SPC1##的化合物，其中R.sub.1代表直链或支链的C.sub.1 -C.sub.6烷基、烯基或炔基基团，或者是用苯基、卤苯基、三氟甲基苯基、(较低的烷氧基)苯基取代的C.sub.1 -C.sub.3烷基基团，或者是含有不超过两个氧、硫和氮的杂原子的5元或6元杂环环的C.sub.1 -C.sub.3烷基基团；R.sub.2代表苯基基团，可选地取代卤素、较低烷基、羟基或较低烷氧基；X和Y代表氧或硫；它们的盐和酯以及其制备方法。该发明的化合物具有出色的利尿和排钠活性，钾离子排泄量非常低，毒性也很低。
• Diuretic and saliuretic sulphamoylbenzoic acids
  申请人：Ciba-Geigy Corporation

  公开号：US04176190A1

  公开（公告）日：1979-11-27

  The invention relates to sulphamoylbenzoic acids of the formula ##STR1## in which R.sub.1 is a substituted or unsubstituted aryl radical, X is oxygen or sulphur, R.sub.2 is hydrogen, lower alkyl or oxa-lower alkyl or an aryl radical, Py is a substituted or unsubstituted 1-pyrrolyl radical and n is an integer from 0 to 4, and salts of these compounds. They are valuable diuretics and saliuretics.

  这项发明涉及公式为##STR1##的磺胺基苯甲酸，其中R.sub.1是取代或未取代的芳基基团，X是氧或硫，R.sub.2是氢、低烷基或氧代低烷基或芳基，Py是取代或未取代的1-吡咯基团，n是0到4的整数，以及这些化合物的盐。它们是有价值的利尿剂和排钠剂。
• BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE
  申请人：Wanaski Stephen

  公开号：US20120004225A1

  公开（公告）日：2012-01-05

  The present invention provides bumetanide, furosemide, piretanide, azosemide, and torsemide analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide, furosemide, piretanide, azosemide, and torsemide analogs and methods for their use. All of these analogs are particularly useful for the treatment and/or prophylaxis of conditions that involve the Na + K + Cl − co-transporter or GABA A receptor including but not limited to addictive disorders, Alzheimer's Disease, anxiety disorders, ascites, autism, bipolar disorder, cancer, depression, endothelial corneal dystrophy, edema, epilepsy, glaucoma, Huntington's Disease, insomnia, ischemia, migraine, migraine with aura, neuropathic pain, nociceptive neuralgia, nociceptive pain, ocular diseases, pain, Parkinson's disease, personality disorders, postherpetic neuralgia, psychosis, schizophrenia, seizure disorders, tinnitus, and withdrawal syndromes.

  本发明提供了丁苯噻唑、呋塞米、匹利他酯、氮杂呋喃硫脲和托瑞米特的类似物以及包含这些类似物的组合物。本发明还提供了含有这些丁苯噻唑、呋塞米、匹利他酯、氮杂呋喃硫脲和托瑞米特类似物的药物组合物以及它们的使用方法。所有这些类似物特别适用于治疗和/或预防涉及Na+K+Cl−共转运体或GABAA受体的疾病，包括但不限于成瘾障碍、阿尔茨海默病、焦虑障碍、腹水、自闭症、躁郁症、癌症、抑郁症、内皮角膜营养不良、水肿、癫痫、青光眼、亨廷顿病、失眠、缺血、偏头痛、带前兆的偏头痛、神经痛、伤害性神经痛、眼部疾病、疼痛、帕金森病、人格障碍、带状疱疹后神经痛、精神病、精神分裂症、癫痫、耳鸣和戒断综合症。
• BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE
  申请人：NeuroPro Therapeutics, Inc.

  公开号：US20150080350A1

  公开（公告）日：2015-03-19

  The present invention provides bumetanide, analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide, analogs and methods for their use. These analogs are particularly useful for the treatment and/or prophylaxis of conditions that involve the Na + K + Cl − co-transporter or GABA A receptor including but not limited to addictive disorders, Alzheimer's Disease, anxiety disorders, ascites, autism, bipolar disorder, cancer, depression, endothelial corneal dystrophy, edema, epilepsy, glaucoma. Huntington's Disease, insomnia, ischemia, migraine, migraine with aura, neuropathic pain, nociceptive neuralgia, nociceptive pain, ocular diseases, pain, Parkinson's disease, personality disorders, postherpetic neuralgia, psychosis, schizophrenia, seizure disorders, tinnitus, and withdrawal syndromes.

  本发明提供了丁苯酞、类似物和包含这些类似物的组合物。本发明还提供了含有这些丁苯酞、类似物的药物组合物以及它们的使用方法。这些类似物特别适用于治疗和/或预防涉及Na+K+Cl−共转运体或GABAA受体的疾病，包括但不限于成瘾性障碍、阿尔茨海默病、焦虑症、腹水、自闭症、双相情感障碍、癌症、抑郁症、内皮角膜营养不良、水肿、癫痫、青光眼、亨廷顿病、失眠症、缺血、偏头痛、伴有先兆的偏头痛、神经痛、痛觉性神经痛、眼部疾病、疼痛、帕金森病、人格障碍、带状疱疹后神经痛、精神病、精神分裂症、癫痫、耳鸣和戒断综合征。
• BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE
  申请人：NeuroPro Therapeutics, Inc.

  公开号：US20170246131A1

  公开（公告）日：2017-08-31

  The present invention provides bumetanide analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide analogs and methods for their use. These analogs are believed useful for the treatment and/or prophylaxis of conditions that involve the Na + K + Cl − co-transporter or GABA A receptor.